Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy
Asian Journal of Current Research in Clinical Cancer · 2022
DOI: 10.51847/0mz81d1ojh ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Current Research in Clinical Cancer, 2022. Verfasst von P. Davies und 2 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Natural killer (NK) cells are a promising avenue for cancer immunotherapy, but efficient clinical-scale production remains challenging. Here, we present an optimized protocol for the activation and expansion of NK cells (NKAE) and its validation under clinical-grade conditions. NK cells were expanded from either total peripheral blood mononuclear cells (PBMCs) or CD45RA+ subsets using irradiated K562 feeder cells expressing IL15-41BBL or IL21-41BBL, with culture media including RPMI-1640, SCGM,
Zitieren
APA
Davies, P., Johnson, S., & Miller, R. (2022). Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy. Asian Journal of Current Research in Clinical Cancer. https://doi.org/10.51847/0mz81d1ojh
Vancouver
Davies P, Johnson S, Miller R. Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy. Asian Journal of Current Research in Clinical Cancer. 2022. doi:10.51847/0mz81d1ojh
BibTeX
@article{Davies2022,
author = {Davies, P. and Johnson, S. and Miller, R.},
title = {Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy},
journal = {Asian Journal of Current Research in Clinical Cancer},
year = {2022},
doi = {10.51847/0mz81d1ojh}
}
EUVIMED